NCT07310277Available不适用
Expanded Access to ABBV-706
AbbVie0 个研究点开始时间: 2025年12月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-706 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Exclusion Criteria:
- •There are other suitable treatment options.
- •The participant qualifies for ongoing clinical trials.
排除标准
- •There are other suitable treatment options.
- •The patient qualifies for ongoing clinical trials.
研究者
相似试验
已完成
2 期
A single-arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjectswith moderate to severe ulcerative colitisUlcerative Colitis2022-501263-41-00Abbvie Deutschland GmbH & Co. KG36
进行中（未招募）
1 期
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)NCT07285694Arsenal Biosciences, Inc.190
Available
不适用
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a TumorNCT07262970Rezolute
招募中
2 期
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)2024-517140-65-00AbbVie Deutschland GmbH & Co. KG76
招募中
2 期
Study of Intravenous ABBV-400 in Combination With Intravenous Budigalimab to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC2024-514465-18-00AbbVie Deutschland GmbH & Co. KG105